Can we select NSCLC patients for immune checkpoint therapy?

The tail effect with immunotherapy

TNM IASLC Classification, 3-y OS M1c: ~8%

5y follow up phase I CA209-003 Trial

PD-L1 > 50% (N=13)

5-yOS: 43%

Nivolumab up to 96 weeks

PD-L1 > 50% (N=138)

3yOS: 29.7%

Pembrolizumab up to PD

3-y OS phase I KEYNOTE 001 Trial

Brahmer – AACR 2017 * Vokes – Ann Oncol 2018 * Eberhardt – J Thorac Oncol 2015 * Leighl– ASCO 2017